Jiaying Tan: I am curious how you see where [the cancer] field has been and where it is going in terms of epigenetics and chromatin?
Jan Korbel: For me, this will be more [from] of an outside perspective, because I'm pursuing more the genetic side than the epigenetic side, but I do notice in our own data that we often find interesting links to epigenetics and chromatin modeling, and Charlie [referring to Charles Roberts] gave a splendid talk yesterday about how he and others have done that as well, are following up on very specific mutation pattern or very specific complexes, how they are mutated, and then have an effect on the epigenome. I personally see the epigenetic cancer field, if it exists, fairly nicely coming together with the genetic field by exploring links between genetic mutations and trying to follow up mechanistically how they can affect the epigenome .. Given that a lot of very striking mutations we see in cancer genomes are mutations affecting epigenetic genes and that when studying these we can learn more about how arresting a certain state and certain differentiation state, which then generates an epigenetic pattern, can contribute to cancer, I see both niches are coming more closely together right now, which is great.
Charles Roberts: I think it's, as you say, a drive toward mechanism. As I look back, when I first started working on chromatin remodeling in cancer, and I went to my first meeting that was dedicated to epigenetics, I was very disappointed, because everything at the meeting was on DNA methylation. The chromatin hadn't really been recognized yet, so there was literally zero other people there working on that type of chromatin or real-life genetic regulation. Then, as the mutations have become known, people more and more started to get into it, and initially the naive view [was] , if it's ''epigenetic'' it must be HDAC inhibitors, and not quite the realization of just how broad and diverse epigenetic or chromatin contributions are to cancer. I really think [of a] two-pronged approach. One is mechanism, really understanding why those mutational things that are broad transcriptional regulators drive cancer. What are the mechanisms that are underlying that? Then at the same time, trying to think about patients. Can we do something for today's patients therapeutically?
JT: You mentioned a really interesting point, Charlie. There's a lot of questions about how HDAC inhibitor [are] actually targeting. As one of the speakers mentioned yesterday, this whole idea of reverse translational research-seeing something in a patient and going back to try to really figure out how it works. Do you think that concept has been applied in terms of targeting epigenetics, or drugs and epigenetics in the cancer field?
CR: I think precisely that has been followed. For us the clue was in 1997 or 1998, when Olivier Delattre published these mutations present in this rare pediatric cancer, in an ATPdependent chromatin remodeling complex, and wondering why an ATP-dependent chromatin remodeling complex looks like it's behaving as a tumor suppressor. We jumped in, armed with also the understanding that often mutations in early onset pediatric cancers can be a harbinger of important processes in cancer much more broadly. Then, beginning in 2010, the tidal wave breaks, and all of these indications of chromatin regulators begin to be recognized as the human cancer genome project really came to fruition. Suddenly, the realization, ''wow!'' these things are prevalent. Bert Vogelstein had said at one of the AACR meetings, not much new was learned from the cancer genome sequencing, except for the frequencies, and then suddenly the next year pointed out what we didn't see was the chromatin regulators. We just didn't know about them, so suddenly a new front to the war in understanding cancer.
JK: I fully agree, and I'm going to take a slightly different angle in my answer using the question to point out our own thoughts of how important mechanisms are to understand genetic and also epigenetic alterations. We've been looking very closely to what extent the [structural] rearrangement of enhancers can contribute to oncogenic overexpression. What we and some others (Rick Young's group for instance) see [is] very strong epigenetic and chromatin effects, and very local, at the topologically associating domain where these rearrangement occur. Studying the mechanism here is extremely helpful. We don't immediately have a drug at hand, but now that we understand, for instance, at the IGF2 locus that a structure akin to a new topologically associating domain is found with a super enhancer, this gives us a better angle [for thinking] about treatment, for instance, inhibiting the super enhanced gene interaction.
JT: I think it's very interesting [that] the definition of epigenetics has been evolving. Initially it was something not in the sequence, then it was very heavy on modification, and now it's seamlessly merged into the whole idea of chromatin structure. This [reflects] how the field has been moving from more a granular level to more an overview in terms of how the genome is really organizing itself and trying to function.
JK: Yes. clearly epigenetics is more than DNA modification, and it should be.
CR: I think Jan put it very well that really epigenetics is an interaction of genetic mutations with transcriptional regulation. If we back up and look where the field has been, in the 1980s the cutting edge of genomics was looking at chromosomal translocations in leukemia, and what those essentially are turns out [to be] oncogenes being translocated into the T cell or B cell receptor loci. Essentially, that is ''enhancer hijacking'' that's driving those. Those have some of the most potent transforming abilities. If you put those into mice, and turn on Myc, [you get] extremely rapid cancer onset, and you get these genotypes in humans that are very simple. To me, as we look forward and see, for instance, with the rhabdoid tumors when you mutate SWI/SNF chromatin subunit, [you] also [get] very simple genomes. It distills a message that transcriptional regulation, in my view, is what cancer in many ways is about, and that the genome instability is an inefficient way to get there.
It's a necessary way for many cancers, in order to rack up the mutations that you need, but it's really about getting to transcriptional dysregulation and if you directly dysregulate transcription in the right ways, you can actually see cancer evolve in very simple genomes. It's a fascinating interplay between the two.
JT: Yesterday there was a talk comparing adult cancer and pediatric cancer. [There is] a question of whether the ultimate differences between them is because of the time that you have to accumulate mutation. Apparently that's not the full story. Jan, have you thought about whether there's some principle you can learn when you look at those very distinct phenotypes at different human ages?
JK: These childhood cancers are mostly rising in the context of cells that are dividing very rapidly, and they're programmed to divide very rapidly, because in children cells need to build up the body, they need to build up our main organs . in my mind the pediatric cancers are mostly cancers where this program of rapid expansion in a non-differentiated state is not arrested as it should be. This appears to require relatively few mutations, which might be the case that the cells actually have many properties of what we typically consider to be the purpose of a tumor, once these mutations act. In adult cancer we see many more mutations arising. We see that the disease peaks much later in age, and it is often strongly driven by environmental influences, like tobacco smoke and UV light in lung and skin cancer, and hence for cells that are not programmed to expand that rapidly, may require many more mutations to convince them to actually start growing again, and to develop the properties of a tumor, to de-differentiate again.
CR: I think that's likely to be precisely it . high population, high frequency of cells, [which] already have many of the transcriptional pathways ''ON'' for hyperproliferation, and so what's necessary to actually push them over the edge is much less. Just as Jan said, in the adult cancers, a much lower frequency, and the cells that are there are often more restricted in their abilities and likely more mutations, therefore, are needed to drive them. And yet there are still core themes that can come through in either case. The transcription factors that are involved in both pediatric and adults, or for example the SWI/SNF complex that we work on, is very clearly mutated in both pediatric and adult, [and there is] a shared theme of certain pathways or mechanisms, but a difference in what's needed to actually get there.
''Suddenly, the realization, ''wow!'' these things are prevalent.'' ''. transcriptional regulation, in my view, is what cancer in many ways is about, and that the genome instability is an inefficient way to get there.'' JK: I found pediatric cancers very interesting because they contain so few mutations. We found it easier to essentially look into certain principles.
JT: It has less noise, so to speak, and bystander phenomena that accumulate over the time. One more question. From your own point of view, what's next big question that you want to tackle?
JK: I'll start with the immediate next question we're tackling. We're currently putting this fairly large database of cancer genomes together .. We've collected approximately 2,800 patients with matched tumor and normal whole genomes. It's a collaborative work between the International Cancer Genome Consortium and it's subprojects including TCGA, and we [are] specifically exploring principles of how can we learn from what's happening in our hereditary genome and the types of mutations we see in the somatic genome. This hasn't been explored so far yet. I think one of the reasons is that we do carry many germline variants in our genome, between three and four million, so we need fairly large sample sizes to make sense of these heritable variances in a statistical manner. We lack power for this. One of the themes we're currently investigating is can we connect the germline variation world with the somatic variation world. There's indeed some fairly interesting links between both that goes beyond high-risk cancer genes such as BRCA1 and BRCA2, which predetermine to some extent how the tumor will mutate. There's more to come here. That's one of the things we are doing in the immediate future.
CR: It's become clear how frequently chromatin regulators are mutated in cancer, SWI/SNF complex is in over 20% of all cancers. [We want to] fundamentally understand the mechanism of why this is happening, always with the goal toward, does that enable us to therapeutically target it? At the first level, we have identified antagonism with the polycomb complex, and it's been exciting to see how rapidly that has moved into the clinic. Now though, I think our understanding is still relatively rudimentary. If we think about this, p53, Ras, and Myc, we've known about for 3 to 4 decades, the involvement of chromatin regulators, in many cases, 5, 6, 7 years, so there's a lot to be discovered with respect to mechanism that we hope, yet to be proven, can inform new ways to go about therapy.
